ProQR Therapeutics NV (NASDAQ:PRQR)

0.8181
Delayed Data
As of 3:57pm ET
 -0.008 / -0.97%
Today’s Change
0.53
Today|||52-Week Range
9.09
-89.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$60.2M

Company Description

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Contact Information

ProQR Therapeutics NV
Zernikedreef 9
Leiden Zuid-holland 2333 CK
P:(188) 166-7000
Investor Relations:
(617) 599-6228

Employees

Shareholders

Other institutional29.24%
Mutual fund holders14.10%
Individual stakeholders--

Top Executives

Daniel Anton de BoerChief Executive Officer
Theresa Marie HeggieChief Operating Officer
Smital ShahChief Financial & Business Officer
Gerard J. PlatenburgChief Scientific Officer
Aniz GirachChief Medical Officer